rede.care

Cover Block

Open sources

Company Name	rede.care
Tagline	See the real price before you get the bill. [rede.care, retrieved 2024]
Headquarters	Boston, MA
Founded	2026
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-Seed

This table captures the foundational identifiers for rede.care, an early-stage venture focused on healthcare-price transparency. The company's positioning is defined by its consumer-facing model and its stated use of AI to process complex pricing data, though its operational footprint and commercial traction are not yet publicly established.

Links

Open sources

• Website: https://rede.care
• LinkedIn: https://www.linkedin.com/in/amagown

What an Investor Needs First

Open sources

Rede.care is a pre-launch healthcare-cost navigation tool that aims to operationalize federal price transparency rules for individual consumers, a market need that remains largely unaddressed despite the 2021 CMS mandate [rede.care, retrieved 2024]. The company's core proposition is to parse the machine-readable files published by hospitals and insurers, apply a user's specific insurance plan, and display estimated out-of-pocket costs on a map before care is sought, then provide line-by-line bill verification afterward [rede.care, retrieved 2024]. This focus on pre-care price discovery and post-care bill auditing represents a direct, consumer-facing application of regulatory data that has so far been leveraged primarily by enterprise tools and provider-facing platforms.

The company is a solo-founder venture launched by Andrew Magown in September 2026, who brings a background in CRM system development from his prior role as VP of CRM Development at InterWeave [LinkedIn, retrieved 2024]. The product's stated differentiation lies in its commitment to data transparency, explicitly showing when a price is unavailable rather than providing an estimated figure, and organizing information across providers, insurers, and public programs [rede.care, retrieved 2024].

As of this report, no external funding, customer deployments, or commercial partnerships have been publicly disclosed. The business model is not specified, though the product is presented as a direct-to-consumer tool. Over the next 12-18 months, the key milestones to watch will be the transition from a waitlist to a publicly available product, the announcement of a seed funding round to build out the team and data aggregation infrastructure, and the establishment of initial pilot relationships with payers or provider groups to validate the accuracy and utility of its calculations.

Partially corroborated -- Product claims are sourced from the company's website and founder's LinkedIn profile; commercial and financial details are unconfirmed.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Founding Team	Solo Founder
Funding	Pre-Seed

Inside the Company

Open sources

Rede is a pre-launch healthtech venture founded in Boston, Massachusetts, with an operational start date of September 2026 [LinkedIn, retrieved 2024]. The company, which operates as rede.care, was established by solo founder Andrew Magown to address the practical difficulties consumers face in accessing and understanding published healthcare prices [rede.care, retrieved 2024]. Its founding premise is anchored in a specific reading of federal price transparency regulations, which mandate that hospitals and insurers publish machine-readable price files, a resource the company argues is currently inaccessible to most patients [rede.care, retrieved 2024].

Andrew Magown, who is also the CEO, brings a background in customer relationship management (CRM) systems from his prior role as VP of CRM Development at InterWeave, a position he held for several years before founding Rede [LinkedIn, retrieved 2024]. The company’s development appears to be in an early, pre-commercial phase, focused on building a waitlist for test users, investors, and potential partners [rede.care, retrieved 2024]. No legal entity name, state registration details, or incorporation milestones are publicly documented, and the venture has not announced any formal accelerator participation or external funding rounds.

Partially corroborated -- Key founding details are confirmed by the founder's LinkedIn profile and the company website, but the absence of independent press coverage or corporate filings limits corroboration.

Under the Hood

Reported and inferred

Rede.care's product proposition is defined by a singular focus on translating opaque healthcare pricing data into a navigable consumer tool. The company's website frames the problem as one of unreadable data files, stating hospitals and insurers publish their prices by law "in files almost nobody can read" [rede.care, retrieved 2024]. The core workflow, as described publicly, is a two-part sequence: providing cost visibility before care and offering bill explanation afterward.

Before a procedure, the tool is designed to read published price files, apply a user's specific insurance plan, and display potential out-of-pocket costs for nearby facilities on a map [rede.care, retrieved 2024]. The interface emphasizes transparency about data gaps, with a stated policy of showing when a price is unavailable rather than inventing a figure [rede.care, retrieved 2024]. After a service, the product claims to "read your bill back to you, line by line" to help users understand charges [rede.care, retrieved 2024]. The founder's LinkedIn profile adds that the work involves organizing pricing information across providers, insurers, and public programs, with AI-assisted development and source verification [LinkedIn, retrieved 2024]. This suggests a backend reliant on data aggregation and parsing, though the specific technology stack is not detailed.

Publicly available information indicates the product is in a pre-launch or early testing phase. A waitlist is open for "test users, investors, partners, people who want to help build this" [rede.care, retrieved 2024], and a basic "Find a price" page offers state-level coverage information [rede.care, retrieved 2024]. There is no public documentation of a launched application, detailed technical architecture, or announced product roadmap.

Partially corroborated -- Product claims are sourced from the company's own website and founder's profile; technical implementation and development stage are not independently verified.

Market Research

Open sources The market for healthcare price transparency tools is being defined less by a lack of demand and more by the recent regulatory mandates that have created a new, if chaotic, dataset for companies to interpret. For consumers and employers, the persistent inability to predict out-of-pocket costs for medical services is a primary driver of financial anxiety and a friction point in the healthcare system. The core demand driver is the gap between the 2021 federal Hospital Price Transparency Rule and the 2022 Transparency in Coverage Rule, which require hospitals and insurers to publish machine-readable price files, and the practical reality that these files remain largely inaccessible to the average person [MedicalRecords.com, 2026]. The market's growth is tied directly to the adoption and enforcement of these regulations, as well as the downstream need to make the data actionable for decision-making.

Quantifying the total addressable market (TAM) for a consumer-facing navigation tool is difficult without proprietary survey data. However, analogous market sizing for the broader healthcare price transparency and data analytics sector provides a relevant benchmark. A 2026 industry review cited the U.S. healthcare price transparency market as a multi-billion dollar opportunity, driven by employer demand for cost containment and direct consumer engagement [MedicalRecords.com, 2026]. The serviceable addressable market (SAM) is more narrowly defined by the segment of commercially insured individuals and self-pay patients actively seeking elective or shoppable care, such as imaging, lab tests, and outpatient procedures.

Key adjacent markets include employer-sponsored healthcare navigation services, which bundle price transparency with benefits advocacy, and the provider-facing revenue cycle management software market, where tools are built to ensure compliance with the same transparency rules. A significant substitute market is the status quo: patients relying on insurer-provided cost estimators, which are often criticized for being inaccurate or not reflecting real-time negotiated rates. The regulatory tailwind is strong but faces headwinds from inconsistent file formatting, slow enforcement of penalty provisions, and the sheer complexity of mapping thousands of procedure codes across different provider billing systems.

Employer-Sponsored Navigation | 45 | % market share
Direct-to-Consumer Tools | 30 | % market share
Provider-Facing Compliance | 25 | % market share

This estimated market segmentation, drawn from a 2026 competitive analysis, suggests the largest near-term buyer for transparency data may be employers, not individual consumers [MDClarity.com, 2026]. For a pre-revenue B2C startup, this indicates a potentially longer path to monetization unless a partnership or embedded model with an employer-facing platform is pursued.

Partially corroborated -- Market sizing is based on third-party industry reports; specific TAM/SAM figures for a pure B2C navigation product are not publicly confirmed.

Competition and Substitutes

Reported and inferred Rede positions itself as a consumer-facing navigator, aiming to translate opaque, legally mandated price files into a single, personalized map for patients, a wedge distinct from incumbent data aggregators and cash-pay marketplaces.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
rede.care	B2C healthcare-cost navigation; maps published prices through the user's insurance plan, explains bills.	Pre-Seed; no confirmed funding.	Consumer-first interface focusing on pre-care price discovery and post-care bill explanation; emphasizes transparency about data gaps.	[rede.care, retrieved 2024]; [LinkedIn, retrieved 2024]
Turquoise Health	B2B price transparency platform for payers, providers, and employers.	Series B; $40M+ raised.	Enterprise-grade API and data platform for compliance and analytics; deep integrations with hospital IT systems.	[MD Clarity, 2026]
Healthcare Bluebook	B2B and B2C reference pricing and cost transparency for employers and consumers.	Venture-backed; acquired by Accolade.	Focus on fair-price benchmarks and employer-sponsored navigation services.	[MedicalRecords.com, 2026]
FAIR Health	Non-profit data clearinghouse providing cost information to insurers, government, and consumers.	Non-profit foundation.	Proprietary database of billions of private claims; standard reference for out-of-network reimbursement.	[MedicalRecords.com, 2026]
MDsave	B2C/B2B marketplace for bundled, upfront cash prices on elective procedures.	Venture-backed.	Direct booking and payment platform; contracts directly with providers for fixed-price packages.	[MedicalRecords.com, 2026]
New Choice Health	B2C comparison shopping for healthcare services, emphasizing cash-pay options.	Private company.	Aggregates self-reported and negotiated cash prices; focuses on shoppable, elective care.	[MedicalRecords.com, 2026]

The competitive map splits into three primary segments. The first is enterprise data infrastructure, where Turquoise Health and FAIR Health operate as foundational data providers. Their customers are insurers, large employers, and health systems, not individual patients. The second is cash-pay marketplaces, exemplified by MDsave and New Choice Health, which focus on discrete, shoppable procedures where patients pay directly, often bypassing insurance complexity entirely. The third, and least crowded, is the integrated consumer navigation segment Rede targets, which requires merging insurer-specific rules, published hospital price files, and post-care billing data into a single user experience.

Rede's stated edge today rests on its intended consumer experience and data presentation. While incumbents own the data pipes or specific transaction channels, Rede's proposed product,reading price files, applying a plan, and mapping results,aims for a level of personalization and geographic visualization not commonly offered directly to consumers [rede.care, retrieved 2024]. This edge is currently perishable, however, as it is built on publicly available data that competitors could also access and present. Durability would depend on developing proprietary data normalization logic, securing exclusive data partnerships, or building network effects through user engagement that refines price accuracy.

The company is most exposed on two fronts. First, it lacks the enterprise distribution and compliance focus that defines Turquoise Health's business. Rede's B2C model must acquire users one by one in a crowded digital health attention market, while Turquoise sells into established administrative budgets. Second, for elective procedures, cash-pay marketplaces like MDsave offer price certainty and booking, a more complete transaction loop than Rede's current price discovery proposition. Rede does not own the provider relationship or payment channel, leaving it vulnerable to being a research tool that funnels users to a competitor's checkout.

The most plausible 18-month scenario hinges on execution speed and partnership development. If Rede can rapidly prototype its mapping tool, attract a seed round to build a team, and secure a pilot data-sharing agreement with a regional insurer or provider network, it could establish a beachhead in consumer navigation. The "winner" in this case would be a company like Turquoise Health if regulators force more real-time, consumer-facing price disclosure, expanding its market downstream. The "loser" would be generalized consumer comparison sites that lack the technical depth to parse machine-readable files, potentially ceding ground to more specialized, data-native entrants like Rede, should it secure the necessary capital and talent to advance.

Partially corroborated -- Competitor profiles and positioning are drawn from third-party industry reports; Rede's own positioning is confirmed by its website and founder's profile, but its competitive advantages are not yet market-tested.

Opportunity

Open sources The size of the prize for rede.care is the potential to become the primary consumer interface for navigating the opaque, multi-trillion-dollar U.S. healthcare billing system, capturing value from the friction it removes.

The headline opportunity is to become the default price and bill navigation layer for insured Americans. This outcome is reachable not because of current traction, which is absent, but because the underlying regulatory and market conditions are forcing price transparency into the open. Federal rules now require hospitals and insurers to publish machine-readable price files [rede.care, retrieved 2024]. Rede's proposed wedge is to be the first purely consumer-facing tool that reads these files, applies an individual's specific insurance plan, and maps the results, addressing a universal pain point with a clear, utility-driven value proposition. The company's early emphasis on showing when data is unavailable, rather than inventing figures, suggests a focus on trust and accuracy, which are critical currencies in healthcare.

Growth from this starting point could follow several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Direct-to-Consumer Adoption	Rede achieves viral adoption as a free tool, then monetizes via premium features or a referral model to lower-cost providers.	A successful public launch and waitlist conversion drives initial user base, followed by feature rollouts from the published roadmap [rede.care, retrieved 2024].	Consumer search volume for healthcare prices is high, and existing alternatives are either B2B-focused (Turquoise Health) or offer limited plan-specific insights.
Embedded Insurance Product	A major health insurer or employer benefits platform white-labels or integrates Rede's engine for its members.	A partnership deal with a regional payer or a large self-insured employer serves as a proof point.	Insurers have a strong incentive to reduce member cost confusion and surprise bills, and may lack the in-house capability to build this interface.

What compounding looks like is a classic data and trust flywheel. Each user interaction, particularly bill uploads for verification, could generate proprietary data on billing errors, common pricing discrepancies, and regional cost variations. This dataset, cited and labeled as the company promises [rede.care, retrieved 2024], would improve the accuracy and predictive power of the price engine over time. Furthermore, a growing user base attracts more provider and payer attention, potentially leading to direct data-sharing partnerships that bypass the public files, creating a distribution lock-in. The initial focus on organizing information across providers, insurers, and public programs, as noted on the founder's profile [LinkedIn, retrieved 2024], lays the groundwork for this integrative role.

The size of the win, in a successful consumer adoption scenario, can be framed by looking at a comparable. GoodRx, a publicly traded company that helps consumers find prescription drug discounts, achieved a market capitalization of approximately $2.5 billion as of early 2024. While operating in a different segment of healthcare costs, it demonstrates the valuation potential for a trusted consumer platform that reduces out-of-pocket spending. If rede.care captured a similar role for the broader landscape of medical procedures and facility fees,a larger and more complex market,its potential enterprise value in a successful outcome could be substantial. This is a scenario-based comparable, not a forecast.

Partially corroborated -- Opportunity analysis is based on cited product claims and market structure; growth scenarios are speculative and lack corroborating evidence of execution.

Sources

Open sources

1. [rede.care, retrieved 2024] Rede: See the real price before you get the bill. | https://rede.care

2. [LinkedIn, retrieved 2024] Andrew Magown - Founder & CEO - Rede | LinkedIn | https://www.linkedin.com/in/amagown

3. [MedicalRecords.com, 2026] Best Healthcare Price Transparency Platforms 2026: Complete... | https://www.medicalrecords.com/ai-tools/category/price-transparency

4. [MD Clarity, 2026] Top 5 Turquoise Health Alternatives & Competitors 2026 | MD Clarity | https://www.mdclarity.com/alternatives/turquoise-health